Kodiak Sciences Inc (KOD): Price and Financial Metrics
KOD Price/Volume Stats
| Current price | $1.95 | 52-week high | $9.80 |
| Prev. close | $1.99 | 52-week low | $1.95 |
| Day low | $1.95 | Volume | 483,600 |
| Day high | $2.02 | Avg. volume | 689,853 |
| 50-day MA | $3.12 | Dividend yield | N/A |
| 200-day MA | $5.76 | Market Cap | 102.28M |
KOD Stock Price Chart Interactive Chart >
Kodiak Sciences Inc (KOD) Company Bio
Kodiak Sciences is a clinical stage biopharma specializing in therapeutics to treat chronic retinal diseases. The company was founded in 2005 and is based in New York City, New York.
Latest KOD News From Around the Web
Below are the latest news stories about KODIAK SCIENCES INC that investors may wish to consider to help them evaluate KOD as an investment opportunity.
Kodiak Sciences Inc. (KOD) Down 19.9% Since Last Earnings Report: Can It Rebound?Kodiak Sciences Inc. (KOD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues. |
Kodiak Sciences to Present at the Morgan Stanley 21st Annual Global Healthcare ConferenceKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Morgan Stanley 21st Annual Global Healthcare Conference in New York, NY on Wednesday, September 13, 2023, at 12:55 p.m. Eastern Time. |
New one-year results for Kodiak's tarcocimab tedromer in the pivotal BEACON trial reinforce durability signal and demonstrate matched efficacy and comparable safety and tolerability in retinal vein occlusionKodiak Sciences Inc. (NASDAQ: KOD) today announced top-line, one-year (48 weeks) results for its ABC Platform based investigational therapy tarcocimab tedromer 5 mg from the pivotal BEACON study in patients with macular edema due to retinal vein occlusion (RVO). |
Owning 49% shares,institutional owners seem interested in Kodiak Sciences Inc. (NASDAQ:KOD),Key Insights Given the large stake in the stock by institutions, Kodiak Sciences' stock price might be vulnerable to... |
Kodiak (KOD) Q2 Earnings Miss, New Lead Candidate in FocusKodiak (KOD) reports weaker-than-expected results in second-quarter 2023. The company also provides an update on the status of its pipeline after discontinuing the tarcocimab program. |
KOD Price Returns
| 1-mo | -13.72% |
| 3-mo | -73.07% |
| 6-mo | -60.45% |
| 1-year | -75.56% |
| 3-year | -81.39% |
| 5-year | N/A |
| YTD | -72.77% |
| 2022 | -57.77% |
| 2021 | -42.29% |
| 2020 | 104.18% |
| 2019 | 913.38% |
| 2018 | N/A |
Loading social stream, please wait...